查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1474920

美国临床前 CRO 市场规模、份额、趋势分析报告：按服务、按模型类型、按技术、按最终用途、按州、细分市场预测，2024-2030 年

U.S. Preclinical CRO Market Size, Share & Trends Analysis Report By Service (Bioanalysis & DMPK Studies, Toxicology Testing), By Model Type, By Technology, By End-use, By State, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10个工作天内

价格

美国临床前CRO市场成长与趋势：

Grand View Research, Inc.最新报告显示，到2030年，美国临床前CRO市场规模预计将达到59亿美元，2024年至2030年复合年增长率为7.1%。

製药公司增加研发活动支出以及注重降低成本是促进市场成长的因素。

早期和后期药物开发过程的研发预算显着增加，预计将有助于市场成长。此外，生物製药失败率和相关成本的上升正促使生物製药和生命科学公司更专注于药物发现和开发过程的早期阶段。这可能会推动临床前 CRO 市场的成长。

全球阿兹海默症患者数量不断增加、对尖端基因疗法的需求、神经退化性疾病的发病率以及遗传性疾病的高盛行率是推动先进治疗方法增长的一些因素。许多大大小小的生物技术公司都在技术和製造能力方面推动该领域的创新，为市场扩张提供了机会。

此外，最近新产品的核准正在加速研发活动。例如，2023年12月，FDA核准了两种突破性治疗方法－Casgevy和Lyfgenia。作为 12 岁及以上镰状细胞疾病患者的第一种基于细胞的基因疗法，这些治疗方法代表了一个重要的里程碑。

美国临床前 CRO 市场报告亮点：

  • 药物发现研究在服务领域占据主导地位，到 2023 年，其份额将达到 29.6%。这是由于生物技术和製药公司越来越倾向于外包研究以加速药物发现并降低成本。
  • 由于CRO在生物分析研究中的广泛应用，生物分析和DMPK研究领域预计将在预测期内呈现最快的复合年增长率。
  • 对个人化医疗和先进疗法的需求不断增长、生命科学公司对核心竞争力的关注以及外包趋势的上升预计将在预测期内推动市场成长。
  • 2022年8月，药明康德STA宣布在美国建立占地190英亩的新製药生产园区。该设施将是该公司的第二个设施，提供扩展能力和弹性，以满足美国和世界各地客户的需求。

目录

第一章调查方法和范围

第 2 章执行摘要

第 3 章美国临床前 CRO 市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 美国临床前CRO市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章美国临床前CRO市场：服务预估与趋势分析

  • 2023年及2030年服务市场占有率
  • 细分仪表板
  • 美国临床前 CRO 市场展望（按服务）
  • 2018-2030年市场规模、预测及趋势分析

第五章美国临床前CRO市场：模型类型估算及趋势分析

  • 2023 年和 2030 年按车型类型市场占有率
  • 细分仪表板
  • 按模型类型分類的美国临床前 CRO 市场展望
  • 2018-2030年市场规模、预测及趋势分析

第六章美国临床前CRO市场：技术预估与趋势分析

  • 2023年及2030年技术市场占有率
  • 细分仪表板
  • 美国临床前CRO市场，依技术分類的前景
  • 2018-2030年市场规模、预测及趋势分析

第七章美国临床前CRO市场：最终用途估算与趋势分析

  • 2023 年及 2030 年最终用途市场占有率
  • 细分仪表板
  • 美国临床前 CRO 市场展望（按最终用途）
  • 2018-2030年市场规模、预测及趋势分析

第八章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商情况
  • 公司简介
    • Laboratory Corporation of America
    • Lonza
    • WuXi AppTec, Inc.
    • Eurofins Scientific SE
    • Intertek Group plc
    • Medpace Holdings, Inc.
    • Charles River Laboratories International, Inc.
    • SGA SA
    • Pharmaceutical Product Development, Inc.（Thermo Fisher Scientific, Inc.）
    • ICON plc
    • CROWN bioscience
Product Code: GVR-4-68040-257-3

U.S. Preclinical CRO Market Growth & Trends:

The U.S. preclinical CRO market size is anticipated to reach USD 5.9 billion by 2030, growing at a CAGR of 7.1% from 2024 to 2030, according to a new report by Grand View Research, Inc. Factors such as the increasing expenditure on R&D activities and the focus of pharmaceutical companies on cost reduction are driving the market growth.

There has been a significant increase in the R&D budget for early-stage and late-stage drug development processes, which is expected to contribute to market growth. The rising biopharmaceutical failure rates and the costs they entail have also driven the biopharmaceutical & life sciences companies to focus more on the early stage of the drug discovery and development process. This is likely to propel the growth of the market for preclinical CRO.

The increasing cases of Alzheimer's disease globally, demand for cutting-edge gene therapies, incidence of neurodegenerative diseases, and high prevalence of genetic disorders are some of the factors promoting the growth of advanced therapies. A substantial number of major & small biotechnology companies are driving innovation in this field in terms of technology & manufacturing capabilities, thereby offering commercial opportunities for market expansion.

Furthermore, the recent approval of new products has accelerated R&D activities. For instance, in December 2023, the FDA approved two groundbreaking treatments-Casgevy and Lyfgenia. These treatments mark a significant milestone as the first cell-based gene therapies suggested for the treatment of sickle cell disease in patients aged 12 and older.

U.S. Preclinical CRO Market Report Highlights:

  • Discovery research dominated the service segment with 29.6% share in 2023, owing to the rising trend of outsourcing research in the biotechnology and pharmaceutical companies to accelerate drug discovery and reduce cost.
  • The bioanalysis and DMPK studies segment is expected to witness the fastest CAGR over the forecast period, owing to widescale applications of CROs in bioanalysis studies.
  • Increasing demand for personalized medicine and advanced therapeutics, life science companies focusing on their core competencies, and the increasing trend of outsourcing are expected to drive the market growth over the forecast period.
  • In August 2022, WuXi STA announced its new 190-acre pharmaceutical manufacturing campus in the U.S. This site would be its second facility, offering expanded capacity and flexibility to meet customers' needs in the U.S. and across the globe.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Services
    • 1.2.2. Model Type
    • 1.2.3. Technology
    • 1.2.4. End-use
    • 1.2.5. States
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Services outlook
    • 2.2.2. Model Type outlook
    • 2.2.3. Technology outlook
    • 2.2.4. End-use outlook
    • 2.2.5. States outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Preclinical CRO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising outsourcing trend
      • 3.2.1.2. Increasing focus of life science companies on their core competencies
      • 3.2.1.3. Increasing demand of personalized medicine and advanced therapeutics
      • 3.2.1.4. Increasing pharmaceutical R&D investments
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Monitoring issues and lack of standardization
      • 3.2.2.2. Managing relationships
  • 3.3. U.S. Preclinical CRO Market Analysis Tools
    • 3.3.1. Industry analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. U.S. Preclinical CRO Market: Services Estimates & Trend Analysis

  • 4.1. Services Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. U.S. Preclinical CRO Market by Services Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Bioanalysis and DMPK studies
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2. In vitro ADME
      • 4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.3. In-vivo PK
      • 4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Toxicology testing
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.2. GLP
      • 4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.3. Non-GLP
      • 4.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Compound management
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.3.2. Process R&D
      • 4.4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.3.3. Custom synthesis
      • 4.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.3.4. Others
      • 4.4.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Chemistry
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.4.2. Medicinal chemistry
      • 4.4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.4.3. Computation chemistry
      • 4.4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5. Safety pharmacology
      • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.6. Discovery research
      • 4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.6.2. Target identification & screening
      • 4.4.6.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.6.3. Target validation & functional informatics
      • 4.4.6.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.6.4. Lead identification & candidate optimization
      • 4.4.6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.6.5. Preclinical development
      • 4.4.6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.6.6. Other associated workflow
      • 4.4.6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.7. Others
      • 4.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Preclinical CRO Market: Model Type Estimates & Trend Analysis

  • 5.1. Model Type Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. U.S. Preclinical CRO Market by Model Type Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Small animal models
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.2. Mice
      • 5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3. Rats
      • 5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.4. Rabbits
      • 5.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.5. Others
      • 5.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Large animal models
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.2. Pig
      • 5.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.3. Others
      • 5.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Organoid models
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Cell culture models
      • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.5. Others
      • 5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Preclinical CRO Market: Technology Estimates & Trend Analysis

  • 6.1. Technology Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. U.S. Preclinical CRO Market by Technology Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. In vivo studies
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. In vitro studies
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Ex vivo studies
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Imaging technologies
      • 6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.4.2. Ultrasound imaging
      • 6.4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.4.3. MRI imaging
      • 6.4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.4.4. CT imaging
      • 6.4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.4.5. Radionuclide imaging
      • 6.4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.4.6. Other imaging technologies
      • 6.4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Other technologies
      • 6.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. U.S. Preclinical CRO Market: End-use Estimates & Trend Analysis

  • 7.1. End-use Market Share, 2023 & 2030
  • 7.2. Segment Dashboard
  • 7.3. U.S. Preclinical CRO Market by End-use Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 7.4.1. Biopharmaceutical companies
      • 7.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 7.4.2. Research and academic institutes
      • 7.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. Medical device companies
      • 7.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company heat map analysis, 2023
  • 8.4. Company Profiles
    • 8.4.1. Laboratory Corporation of America
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Lonza
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. WuXi AppTec, Inc.
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Eurofins Scientific SE
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Intertek Group plc
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Medpace Holdings, Inc.
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Charles River Laboratories International, Inc.
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. SGA SA
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Pharmaceutical Product Development, Inc. (Thermo Fisher Scientific, Inc.)
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. ICON plc
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives
    • 8.4.11. CROWN bioscience
      • 8.4.11.1. Company overview
      • 8.4.11.2. Financial performance
      • 8.4.11.3. Product benchmarking
      • 8.4.11.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. preclinical CRO market, by services, 2018 - 2030 (USD Million)
  • Table 4 U.S. preclinical CRO market, by bioanalysis and DMK studies, 2018 - 2030 (USD Million)
  • Table 5 U.S. preclinical CRO market, by toxicology testing, 2018 - 2030 (USD Million)
  • Table 6 U.S. preclinical CRO market, by compound management, 2018 - 2030 (USD Million)
  • Table 7 U.S. preclinical CRO market, by chemistry, 2018 - 2030 (USD Million)
  • Table 8 U.S. preclinical CRO market, by safety pharmacology, 2018 - 2030 (USD Million)
  • Table 9 U.S. preclinical CRO market, by discovery research, 2018 - 2030 (USD Million)
  • Table 10 U.S. preclinical CRO market, by others, 2018 - 2030 (USD Million)
  • Table 11 U.S. preclinical CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 12 U.S. preclinical CRO market, by small animal models, 2018 - 2030 (USD Million)
  • Table 13 U.S. preclinical CRO market, by large animal models, 2018 - 2030 (USD Million)
  • Table 14 U.S. preclinical CRO market, by organoid models, 2018 - 2030 (USD Million)
  • Table 15 U.S. preclinical CRO market, by cell culture models, 2018 - 2030 (USD Million)
  • Table 16 U.S. preclinical CRO market, by others, 2018 - 2030 (USD Million)
  • Table 17 U.S. preclinical CRO market, by technology, 2018 - 2030 (USD Million)
  • Table 18 U.S. preclinical CRO market, by in vivo studies, 2018 - 2030 (USD Million)
  • Table 19 U.S. preclinical CRO market, by in vitro studies, 2018 - 2030 (USD Million)
  • Table 20 U.S. preclinical CRO market, by ex vivo studies, 2018 - 2030 (USD Million)
  • Table 21 U.S. preclinical CRO market, by imaging technologies, 2018 - 2030 (USD Million)
  • Table 22 U.S. preclinical CRO market, by other technologies, 2018 - 2030 (USD Million)
  • Table 23 U.S. preclinical CRO market, by end-use, 2018 - 2030 (USD Million)
  • Table 24 U.S. preclinical CRO market, by biopharmaceutical companies, 2018 - 2030 (USD Million)
  • Table 25 U.S. preclinical CRO market, by research and academic institutes, 2018 - 2030 (USD Million)
  • Table 26 U.S. preclinical CRO market, by medical device companies, 2018 - 2030 (USD Million)
  • Table 27 U.S. preclinical CRO market, by states, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 U.S. preclinical CRO market: market outlook
  • Fig. 9 U.S. preclinical CRO competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 U.S. preclinical CRO market driver impact
  • Fig. 14 U.S. preclinical CRO market restraint impact
  • Fig. 15 U.S. preclinical CRO market: Services movement analysis
  • Fig. 16 U.S. preclinical CRO market: Services outlook and key takeaways
  • Fig. 17 Bioanalysis and DMPK studies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 In vitro ADME market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 In vivo PK market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Toxicology testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 GLP market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Non-GLP market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Compound management market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Process R&D market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Custom synthesis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Chemistry market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Medicinal chemistry market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Computation chemistry market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Safety pharmacology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Discovery research market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Target identification & screening market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Target validation & functional informatics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Lead identification & candidate optimization market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Preclinical development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Other associated workflow market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 U.S. preclinical CRO market: Model type movement analysis
  • Fig. 39 U.S. preclinical CRO market: Model type outlook and key takeaways
  • Fig. 40 Small animal models market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Mice model market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Rats model market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Rabbits model market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Other model market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Large animal models market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Pigs model market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Other model market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Organoid models market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Cell culture models market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 U.S. preclinical CRO market: Technology movement analysis
  • Fig. 52 U.S. preclinical CRO market: Technology outlook and key takeaways
  • Fig. 53 In vivo studies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 In vitro studies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Ex vivo market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Imaging technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Ultrasound imaging market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 MRI imaging market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 CT imaging market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Radionuclide imaging market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Other imaging technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Other technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 U.S. preclinical CRO market: End-use movement analysis
  • Fig. 64 U.S. preclinical CRO market: End-use outlook and key takeaways
  • Fig. 65 Biopharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Research and academic institutes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Medical device companies market estimates and forecasts, 2018 - 2030 (USD Million)